The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions.
Igor OdintsovAllan J W LuiWhitney J SissoEric GladstoneZebing LiuLukas DelasosRenate I KurthExequiel M SissoMorana VojnicInna KhodosMarissa S MattarElisa de StanchinaShawn M LelandMarc LadanyiRomel SomwarPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Seribantumab treatment blocked activation of the four ERBB family members and of downstream signaling, leading to inhibition of NRG1 fusion-dependent tumorigenesis in vitro and in vivo in breast, lung, and ovarian patient-derived cancer models.